Tag archive for ‘Dr. Eva Feldman’
Neuralstem: Update on Phase I Trial of Neural Stem Cells in ALS is Encouraging (CUR, $1.45)
Purpose of Report An encouraging update on the phase I trial of Neuralstem’s (CUR) neural stem cells in ALS was just presented. I alerted investors about this potential catalyst in my recent blog. Investment Conclusion Before I state my conclusions let me quote the lead investigator on the study, Dr. Eva Feldman. She said […]